Literature DB >> 23050614

MicroRNA-155 is a predictive marker for survival in patients with clear cell renal cell carcinoma.

Shunsuke Shinmei1, Naoya Sakamoto, Keisuke Goto, Kazuhiro Sentani, Katsuhiro Anami, Tetsutaro Hayashi, Jun Teishima, Akio Matsubara, Naohide Oue, Yasuhiko Kitadai, Wataru Yasui.   

Abstract

OBJECTIVES: To investigate the clinical significance of micro-ribonucleic acid-155 in clear cell renal cell carcinoma, in particular focusing on the association of expression levels of micro-ribonucleic acid-155 with clinicopathological factors, cancer-specific survival and therapeutic outcomes in clear cell renal cell carcinoma patients.
METHODS: Quantitative reverse transcription polymerase chain reaction of micro-ribonucleic acid-155 was carried out on 137 clear cell renal cell carcinoma cases, containing 77 matched pairs of clear cell renal cell carcinoma and normal adjacent kidney tissues from the same patients.
RESULTS: Significant overexpression of micro-ribonucleic acid-155 was found in clear cell renal cell carcinoma compared with normal kidney tissue. Expression of micro-ribonucleic acid-155 was not associated with prognosis in all stage groups. However, in 43 patients with stage III and IV clear cell renal cell carcinoma, low expression levels of micro-ribonucleic acid-155 correlated with a poor prognosis. Regarding cancer-free survival of 26 patients with stage III and IV clear cell renal cell carcinoma who received curative resection and cancer-specific survival of 31 patients who received postoperative therapy with interferon-α after radical nephrectomy, low expression levels of micro-ribonucleic acid-155 correlated with poor clinical outcomes in these two groups.
CONCLUSIONS: Low expression of micro-ribonucleic acid-155 represents a valuable marker of poor clinical outcomes in patients with stage III and IV clear cell renal cell carcinoma.
© 2012 The Japanese Urological Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23050614     DOI: 10.1111/j.1442-2042.2012.03182.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  11 in total

Review 1.  The regulation and function of microRNAs in kidney diseases.

Authors:  Qingqing Wei; Qing-Sheng Mi; Zheng Dong
Journal:  IUBMB Life       Date:  2013-07       Impact factor: 3.885

2.  Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers.

Authors:  Katrien Van Roosbroeck; Francesca Fanini; Tetsuro Setoyama; Cristina Ivan; Cristian Rodriguez-Aguayo; Enrique Fuentes-Mattei; Lianchun Xiao; Ivan Vannini; Roxana S Redis; Lucilla D'Abundo; Xinna Zhang; Milena S Nicoloso; Simona Rossi; Vianey Gonzalez-Villasana; Rajesha Rupaimoole; Manuela Ferracin; Fortunato Morabito; Antonino Neri; Peter P Ruvolo; Vivian R Ruvolo; Chad V Pecot; Dino Amadori; Lynne Abruzzo; Steliana Calin; Xuemei Wang; M James You; Alessandra Ferrajoli; Robert Orlowski; William Plunkett; Tara M Lichtenberg; Ramana V Davuluri; Ioana Berindan-Neagoe; Massimo Negrini; Ignacio I Wistuba; Hagop M Kantarjian; Anil K Sood; Gabriel Lopez-Berestein; Michael J Keating; Muller Fabbri; George A Calin
Journal:  Clin Cancer Res       Date:  2016-11-30       Impact factor: 12.531

3.  High MCM6 Expression as a Potential Prognostic Marker in Clear-cell Renal Cell Carcinoma.

Authors:  Nu-Ri Jang; Jina Baek; Younghwii Ko; Phil Hyun Song; Mi-Jin Gu
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.406

Review 4.  MicroRNAs in renal cell carcinoma: a systematic review of clinical implications (Review).

Authors:  Ming Li; Ying Wang; Yongsheng Song; Renge Bu; Bo Yin; Xiang Fei; Qizhen Guo; Bin Wu
Journal:  Oncol Rep       Date:  2015-02-13       Impact factor: 3.906

5.  A three-microRNA signature as a diagnostic and prognostic marker in clear cell renal cancer: An In Silico analysis.

Authors:  Bin Liang; Jianying Zhao; Xuan Wang
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240

6.  [Association of MiR-155 expression with prognosis in resected 
stage III non-small cell lung cancer].

Authors:  Yi Gao; Shengling Fu; Wenyang Jiang; Binfeng Li; Yitao Tian; Xiangning Fu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2014-05

7.  Identification of biomarkers and construction of a microRNA‑mRNA regulatory network for clear cell renal cell carcinoma using integrated bioinformatics analysis.

Authors:  Miaoru Han; Haifeng Yan; Kang Yang; Boya Fan; Panying Liu; Hongtao Yang
Journal:  PLoS One       Date:  2021-01-12       Impact factor: 3.240

8.  MicroRNA-148a is downregulated in gastric cancer, targets MMP7, and indicates tumor invasiveness and poor prognosis.

Authors:  Naoya Sakamoto; Yutaka Naito; Naohide Oue; Kazuhiro Sentani; Naohiro Uraoka; Htoo Zarni Oo; Kazuyoshi Yanagihara; Kazuhiko Aoyagi; Hiroki Sasaki; Wataru Yasui
Journal:  Cancer Sci       Date:  2014-01-06       Impact factor: 6.716

Review 9.  MicroRNAs as prognostic molecular signatures in renal cell carcinoma: a systematic review and meta-analysis.

Authors:  Liangyou Gu; Hongzhao Li; Luyao Chen; Xin Ma; Yu Gao; Xintao Li; Yu Zhang; Yang Fan; Xu Zhang
Journal:  Oncotarget       Date:  2015-10-20

10.  Promoter DNA methylation analysis reveals a novel diagnostic CpG-based biomarker and RAB25 hypermethylation in clear cell renel cell carcinoma.

Authors:  Yinmin Gu; Yi Ming Zou; Danqing Lei; Yuanjie Huang; Weidong Li; Zengnan Mo; Yanling Hu
Journal:  Sci Rep       Date:  2017-10-27       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.